Mediwound (MDWD) : 10-year performance

• ticker: MDWD
  

MediWound (MDWD) : 4-month performance

• ticker: MDWD

MediWound (MDWD) began trading on the NASDAQ on 20 March 2014

• ticker: MDWD

Description

MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing, manufacturing and commercializing products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. The Company’s biopharmaceutical product, NexoBrid, which is based on its patented proteolytic enzyme technology, represents a new paradigm in burn care management, and its clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier upon patient admission, without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary, targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.

Address

42 Hayarkon Street, Industrial Zone
YAVNE, ZF 8122745
Israel

Website 

http://www.mediwound.com

Biotech IPOs this week: Akebia Therapeutics (AKBA), Versartis (VSAR), MediWound (MDWD)

Three biotechnology IPOs are coming up this week that might be worth watching, given how well that most of those launched in the last few months have done….

First on the list is Akebia Therapeutics, whose symbol will be AKBA. IPO Renaissance Capital says the strike price should be somewhere between $14 to $17 a share, with 4.9 million shares expected to hit the market.

Akebia specializes in treating anemia through a rather unusual method — adopting the mountain life. That’s an oversimplification, but the company has discovered that simulating high-altitude conditions can increase red blood cell production and stabilize iron supply in bone marrow. That, in turn, helps to fight anemia.

The second making its debut is Versartis Inc., going by the symbol VSAR. A total 4.6 million shares are to be filed at $16 to $19 apiece. It is developing an orphan drug consisting of a hormone designed to treat pediatric growth deficiency.

IPO Boutique sent out a note Tuesday increasing its rating on the shares on word that the upcoming listing is getting “a great deal of attention from the Street.”  On Monday, IPO Boutique said the offering is “multiple times oversubscribed.”

Finally, the third is Israeli-based MediWound Ltd., whose symbol will be MDWD. A total 5 million shares are up for grabs at $14 to $16 apiece.

This company makes an agent known as NexoBrid, used to remove dead skin left from severe burns. It has already been approved for use by the European Medicines Agency. That was enough for CNBC’s Jim Cramer to declare the stock a standout from the other two on his “Mad Money” program this week.

MediWound Ltd., an Israeli biotech company, files for IPO

MediWound Ltd., an Israeli biotech company, said it’s planning an initial public offering a week after Varonis Systems (VRNS) Inc. raised $105.6 million in an IPO in New York.

• ticker: MDWD

MediWound said yesterday that it plans to sell as much as $80 million of shares in an IPO on the Nasdaq Stock Market. Varonis Systems, a New York-based security software designer that was founded by Israeli entrepreneurs, sold 4.8 million shares at $22 a piece on Feb 27. The stock doubled to $44 on the first day of trading and climbed 4.2 percent yesterday.

Israeli companies are finding investor demand for share offerings even as Russia’s military incursion into Ukraine roils global markets because many of the IPOs from the Middle Eastern country last year rallied, according to Rudy Balseiro, the managing director of equity capital markets at Needham & Co. Wix.com Ltd., an Israeli provider of online tools that help create websites, and Kamada Ltd., a maker of treatments for hereditary lung disease, soared more than 80 percent since their debut last year.

“Whenever something performs, folks always come back looking for more,” Balseiro said in a telephone interview from New York. “It’s growth companies, the market is as open as it’s been for awhile for emerging growth equity, and that’s what Israel is giving us.”

Compugen Ltd., a biotechnology company using computer algorithms to identify targets for cancer drugs, took advantage of an 80 percent surge in the stock since Aug. 5 to sell 6 million shares last month.

A 78 percent jump in the Nasdaq Biotechnology Index in the past 12 months is also luring health-care companies.